Esperion to Participate in Upcoming Virtual Cowen 42nd Annual Healthcare Conference
24. Februar 2022 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Chief Medical Officer, Dr. JoAnne Foody, will participate in a Cardiometabolic/NASH focused panel, in...
Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL® (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021
12. November 2021 07:00 ET
|
Esperion Therapeutics, Inc.
- Analysis of pooled Phase 3 data showed that NEXLETOL [bempedoic acid (BA)] alone lowered LDL-C levels comparable to that of a moderate- or high-intensity statin (≥ 30%) in nearly 1 out of 3 of...
Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update
02. November 2021 07:00 ET
|
Esperion Therapeutics, Inc.
– Recently Announced Transformative Plan to Align Operational and Expense Structure to the Current Environment and Position for Long-Term Growth – – Unprecedented CLEAR Outcomes Study Remains...
Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021
01. November 2021 16:01 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of three abstracts at the American Heart Association (AHA) Scientific Sessions 2021...
Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors
01. November 2021 07:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Seth H.Z. Fischer as a Class III director, with a term expiring at the 2022 meeting of...
ESPERION Announces Plan for Transformative Long-Term Growth
18. Oktober 2021 07:00 ET
|
Esperion Therapeutics, Inc.
–Optimizes organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes trial– –Reduces overall workforce by 40...
Esperion to Report Third Quarter 2021 Financial Results November 2, 2021
12. Oktober 2021 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2021 financial results before the open of the U.S. financial markets on...
ESPERION to Host Investor Webinar on the Current Landscape and Future Directions in the Treatment of Elevated Cholesterol
07. September 2021 16:01 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the lipid management company, today announced that it will host an investor webinar on the current landscape and future...
ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update
04. Mai 2021 16:01 ET
|
Esperion Therapeutics, Inc.
– U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price – – Prescriptions Grew 46% Sequentially; More Than 35,000 Patients now on NEXLETOL® (bempedoic acid) Tablets and...
Esperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL® (bempedoic acid) Tablet in American Heart Journal
27. April 2021 08:00 ET
|
Esperion Therapeutics, Inc.
– First-of-its-kind outcomes trial designed to assess cardiovascular risk reduction in patients with documented intolerance to statin therapy –– Nearly half of trial participants are women, a...